Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Ranjana Advani, MD, Andy I. Chen, MD, PhD, Daniel Lebovic, MD, Mark W. Brunvand, MD, Andre Goy, MD, Julie E. Chang, MD, Ephraim Hochberg, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 4399.

https://doi.org/10.1182/blood.V122.21.4399.4399

Published: 2013

Journal Articles

Hematopoietic Cell Transplantation After Reduced Intensity Conditioning for Severe Paroxysmal Nocturnal Hemoglobinuria:

Rafic Farah, Georg Franke, MD, Tara B. Gregory, MD, Mark W. Brunvand, MD, Thoralf Lange, Rainer Storb, MD, Robert P. Witherspoon

Blood (2011) 118 (21): 2047.

https://doi.org/10.1182/blood.V118.21.2047.2047

Published: 2011

Journal Articles

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Jonathan W. Friedberg, MD, Julie M. Vose, M.D., Brad S Kahl, MD, Mark W. Brunvand, MD, Andre Goy, MD, Yvette L. Kasamon, Bart Burington, Ph.D, Jing Li, PhD, William Ho, MD, PhD, Bruce D. Cheson, MD

Blood (2009) 114 (22): 3742.

https://doi.org/10.1182/blood.V114.22.3742.3742

Published: 2009

Journal Articles

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Sibling or Unrelated Donor Hematopoietic Cell Transplants in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Tara Gregory, MD, Mark W. Brunvand, MD, Peter A. McSweeney, MD, Scott I. Bearman, MD, Michael Maris, MD, Jeffrey Matous, MD

Blood (2009) 114 (22): 3354.

https://doi.org/10.1182/blood.V114.22.3354.3354

Published: 2009

Journal Articles

Interim Analysis of a Phase II Trial of Bortezomib in Patients with Multiple Myeloma Who Failed To Achieve a Complete Response to Autologous Peripheral Blood Stem Cell Transplantation.

Robert M. Rifkin, MD, Roy A. Beveridge, MD, Mark W. Brunvand, MD, Gary Spitzer, MD, Boehm A. Kristi, MS, Mary Ann Rauch, BS, Feng Zhan, PhD, Lina Asmar, PhD

Blood (2005) 106 (11): 5176.

https://doi.org/10.1182/blood.V106.11.5176.5176

Published: 2005

Journal Articles

Preliminary Data on Once-Daily IV Busulfan at 3.2 mg/kg/day Indicate That It Is Safe as a Component of the Conditioning Regimen for Hematopoietic Stem Cell Transplantation.

Mark W. Brunvand, MD, Robert Rifkin, MD, Jeffry V. Matous, MD, Peter McSweeney, MD, Scott Bearman, MD

Blood (2004) 104 (11): 5033.

https://doi.org/10.1182/blood.V104.11.5033.5033

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Hematopoietic Cell Transplantation After Reduced Intensity Conditioning for Severe Paroxysmal Nocturnal Hemoglobinuria:

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Sibling or Unrelated Donor Hematopoietic Cell Transplants in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Interim Analysis of a Phase II Trial of Bortezomib in Patients with Multiple Myeloma Who Failed To Achieve a Complete Response to Autologous Peripheral Blood Stem Cell Transplantation.

Preliminary Data on Once-Daily IV Busulfan at 3.2 mg/kg/day Indicate That It Is Safe as a Component of the Conditioning Regimen for Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Hematopoietic Cell Transplantation After Reduced Intensity Conditioning for Severe Paroxysmal Nocturnal Hemoglobinuria:

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Sibling or Unrelated Donor Hematopoietic Cell Transplants in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Interim Analysis of a Phase II Trial of Bortezomib in Patients with Multiple Myeloma Who Failed To Achieve a Complete Response to Autologous Peripheral Blood Stem Cell Transplantation.

Preliminary Data on Once-Daily IV Busulfan at 3.2 mg/kg/day Indicate That It Is Safe as a Component of the Conditioning Regimen for Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only